We use first and third-party cookies to offer our services and collect statistical data. If you continue browsing this website you accept their use. More information Accept
LESVI Neuraxpharm offers a full manufacturing service for

FINISHED DOSAGE FORMS
OF PHARMACEUTICALS

that are customised and based on our own developments

LESVI

is mainly active in the CNS area, however our portfolio also consists of antiemetic, anti-infective, cardiovascular, pain and respiratory products.

  • CNS 
PHARMACEUTICALS
    CNS
    PHARMACEUTICALS
    MORE
  • CNS 
NUTRACEUTICALS
    CNS
    NUTRACEUTICALS
    MORE
  • OTHER 
PHARMACEUTICALS
    OTHER
    PHARMACEUTICALS
    MORE
  • UNIQUE 
DOSAGE FORMS
    UNIQUE
    DOSAGE FORMS
    MORE
ORAL SOLID AND STERILE FORMS EXPERTISE
Expertise in oral solid dosage forms, steriles and blow-fill-seal technology
MORE
Respiratory APIs

Lesvi is driven by Research and Development. That is reflected in the NUMBER OF PRODUCTS SUPPLIED AND DISTRIBUTED
all over the world and in the loyalty of our clients

8 EU CEPs GRANTED

> 130

MOLECULES IN CNS

13 US DMFs filed

> 270

INVENTIONS

 Japan 8 DMFs

> 1200

PATENTS WORLWIDE

>270 inventions generating >1.200 patents worldwide

MORE
HOME_METAS_INHOUSE_MICRO_ALT

BLOW-FILL-SEAL
SINGLE-DOSE-UNITS
(BFS TECNOLOGY)

Lesvi offers Contract Manufacturing services to produce products in preservative-free unit-dose containers for ophthalmic, otic and other applications

MORE
Neuraxpharm

Lesvi is part of Neuraxpharm, a leading European specialty pharmaceutical company in the treatment of central nervous system disorders (CNS). 

Neuraxpharm develops and commercializes branded and generic CNS pharmaceuticals and nutraceuticals related to the prevention of CNS indications. 

Additionally, through its manufacturing companies Lesvi and Inke, Neuraxpharm has an international presence in more than 50 countries. It provides industry partners with finished dosage forms (FDFs) across multiple technologies and niche active pharmaceutical ingredients (APIs).

MORE

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.

© Neuraxpharm / LESVI. All rights reserved.